A Study to Evaluate SHR-1210 in Combination With Famitinib Plus Chemotherapy in Subjects With NSCLC.

NCT04619433 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

48

Enrollment

INDUSTRY

Sponsor class

Stopped Terminated by Sponsor

Conditions

Non-squamous Non-small-cell Lung Cancer

Interventions

DRUG: Camrelizumab;Pemetrexed and Carboplatin; Famitinib;
DRUG: Camrelizumab;Pemetrexed and Carboplatin;Placebo

Sponsor

Jiangsu HengRui Medicine Co., Ltd.